Shanghai De Novo Pharmatech announced that DN1508052’s Investigational New Drug (IND) has passed United States Food and Drug Administration’s (FDA) review on Novermber 20, 2018. DN1508052 is an investigational highly selective and potent agonist of TLR8, for cancer immunotherapy.